Investigators reviewed existing clinical data to examine whether two ADHD medications—lisdexamfetamine (LDX) and atomoxetine (ATX)—might mitigate the subjective cognitive complaints commonly labeled as brain fog during the menopausal transition. The review targeted cisgender women aged 45–60 whose last menstrual cycle occurred within the prior 10 years. The source did not provide detailed trial counts, dosing schedules, or sample sizes.
The study team framed the question on two fronts: do ADHD medications improve menopausal cognitive symptoms, and do women with greater ADHD symptom burden struggle more during menopause? The authors reported this work stems from prior investigations into how estrogen interacts with ADHD pharmacotherapy and from clinicians’ observations that cognitive slowing is a frequent midlife complaint.
Investigators reasoned that both LDX (a stimulant) and ATX (a non-stimulant) act to enhance dopamine and norepinephrine signaling in the prefrontal cortex. The study team proposed that declining estrogen during perimenopause may reduce these neurotransmitter systems’ activity, producing the subjective cognitive changes patients describe—hence the rationale for repurposing ADHD agents in this context.
Data from the trials the reviewers examined indicated that participants reported meaningful improvements in executive function after receiving either LDX or ATX compared with placebo. These self-reported gains concentrated on working memory and flexible thinking—areas patients commonly cite when they describe losing their train of thought, struggling to organize tasks, or feeling less sharp at work.
The study team observed that both stimulant and non-stimulant mechanisms led to improvements on patient-rated scales. The source emphasized that these are perceived, day-to-day functional changes captured by self-report instruments rather than performance on laboratory measures. Investigators noted that such scales reflect the lived experience of women managing cognitive complaints during the menopausal transition, and so have clinical relevance even when objective tests are unchanged.
Authors told Medical News Today that the observed self-reported benefits support the hypothesis linking estrogen-related neurotransmitter decline to menopausal brain fog. They suggested that clinicians could consider screening midlife women for ADHD symptoms and weighing these medications in cases where menopause hormone therapy is contraindicated or undesired. The source did not specify clinical protocols, off-label guidance, or monitoring frameworks for such use.
The reviewers also summarized objective neurocognitive test results from the same data set and found little to no evidence that LDX or ATX produced measurable improvements on standard lab-based assessments of working memory or sustained attention. The study team reported that, despite clear changes in self-report scores, performance-based metrics did not mirror those subjective gains.
Authors discussed two potential explanations. First, standard cognitive tests may not capture the subtle, real-world executive difficulties women describe; second, the clinical trials included in the review may have been underpowered to detect modest objective effects. The source explicitly stated that larger trials and improved measurement tools are needed. The team told Medical News Today they plan to publish the full review so clinicians can better interpret these findings and apply screening strategies to midlife patients.
Limitations and remaining questions
The article and the investigators were careful to list limitations. The source did not report granular trial methodology, dosing, participant numbers, or statistical details; therefore, readers should interpret the findings as preliminary. Investigators acknowledged heterogeneity across studies in outcome measures and the reliance on self-reported scales, which measure perceived—rather than objectively verified—cognitive change.
Unanswered clinical questions noted by the authors include the optimal candidate profile for treatment, dosing and duration needed to produce durable benefits, and safety considerations specific to the perimenopausal population. The reviewers called for larger, well-powered randomized trials with standardized, ecologically valid outcome measures to determine whether observed subjective gains translate into measurable cognitive improvement and real-world functional benefit.
The study team intends to publish the full review in the peer-reviewed literature and recommended clinicians consider screening for ADHD symptoms in midlife women and weighing lisdexamfetamine or atomoxetine when hormone therapy is not an option; beyond that, the authors did not outline regulatory milestones or formal guideline changes in the source.